Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Mansoor Raza Mirza

ENGOT-ov-6/TRINOVA-2: Randomised, Double-Blind, Phase 3 Study of Pegylated Liposomal Doxorubicin Plus Trebananib or Placebo in Women With Recurrent Partially Platinum-Sensitive or Resistant Ovarian Cancer

European Journal of Cancer

Cancer Research

Oncology

2017

English

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer

International Journal of Gynecological Cancer

English

Related publications

Randomized Phase II Study of the PDGFRα Antibody Olaratumab Plus Liposomal Doxorubicin Versus Liposomal Doxorubicin Alone in Patients With Platinum-Refractory or Platinum-Resistant Advanced Ovarian Cancer

English

Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive, Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial

The Lancet Oncology

Oncology

2017

English

Non‑pegylated Liposomal Doxorubicin for Patients With Recurrent Ovarian Cancer: A Multicentric Phase II Trial

English

Docetaxel and Dasatinib or Placebo in Men With Metastatic Castration-Resistant Prostate Cancer (READY): A Randomised, Double-Blind Phase 3 Trial

The Lancet Oncology

Oncology

2013

English

LBA40_PRARIEL3: A Phase 3, Randomised, Double-Blind Study of Rucaparib vs Placebo Following Response to Platinum-Based Chemotherapy for Recurrent Ovarian Carcinoma (OC)

English

Veliparib and Topotecan for Patients With Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer With BRCA Negative or Unknown BRCA Status

Cancer Treatment and Research Communications

Cancer Research

Oncology

2018

English

Emerging Pharmacotherapies in Ovarian Cancer: Focus on Pegylated Liposomal Doxorubicin

Clinical Medicine Reviews in Women's Health

2010

English

Phase 1–2 Study of Docetaxel Plus Aflibercept in Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

The Lancet Oncology

Oncology

2011

English

Prm212 - Patient Experience With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Mansoor Raza Mirza

ENGOT-ov-6/TRINOVA-2: Randomised, Double-Blind, Phase 3 Study of Pegylated Liposomal Doxorubicin Plus Trebananib or Placebo in Women With Recurrent Partially Platinum-Sensitive or Resistant Ovarian Cancer

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer

Related publications

Randomized Phase II Study of the PDGFRα Antibody Olaratumab Plus Liposomal Doxorubicin Versus Liposomal Doxorubicin Alone in Patients With Platinum-Refractory or Platinum-Resistant Advanced Ovarian Cancer

Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive, Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial

Non‑pegylated Liposomal Doxorubicin for Patients With Recurrent Ovarian Cancer: A Multicentric Phase II Trial

Docetaxel and Dasatinib or Placebo in Men With Metastatic Castration-Resistant Prostate Cancer (READY): A Randomised, Double-Blind Phase 3 Trial

LBA40_PRARIEL3: A Phase 3, Randomised, Double-Blind Study of Rucaparib vs Placebo Following Response to Platinum-Based Chemotherapy for Recurrent Ovarian Carcinoma (OC)

Veliparib and Topotecan for Patients With Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer With BRCA Negative or Unknown BRCA Status

Emerging Pharmacotherapies in Ovarian Cancer: Focus on Pegylated Liposomal Doxorubicin

Phase 1–2 Study of Docetaxel Plus Aflibercept in Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Prm212 - Patient Experience With Platinum-Resistant or Platinum-Refractory Ovarian Cancer